Details of the Drug Combinations

General Information of This Drug (ID: DMR6UL8)

Drug Name

CT-064 DMR6UL8

Synonyms

Ibandronate sodium monohydrate; 138926-19-9; Ibandronate sodium hydrate; UNII-J12U072QL0; Ibandronate (Sodium Monohydrate); J12U072QL0; Bondenza; sodium hydrate hydrogen {1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonate; Monosodium [1-hydroxy-3-(methylpentylamino)propane-1,1-diyl]diphosphonate monohydrate; Destara; Ibandronate sodium [USAN:JAN]; hydroxy-[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphinate

Indication

Disease Entry	ICD 11	Status	REF
Osteoporosis	FB83.0	NDA filed	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
CT-064 + Idarubicin	DCHNIZW	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of Chugai Pharmaceutical.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.